Drugs / Amoxicillin-Potassium Clavulanate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT02783404 | Feb 2017 → Dec 2021 | endocarditis | University of Santiago de Compostela | Terminated | No outcome recorded |
| Phase 4 | NCT01919411 | Feb 2013 → Sep 2018 | sinusitis | Massachusetts Eye and Ear Infirmary | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT02115776 | Jan 2014 → Apr 2015 | bacterial infectious disease | University of Santiago de Compostela | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02935374 Comparator | Nov 2016 → Mar 2020 | otitis media | University of Oulu | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amoxicillin-Potassium Clavulanate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02935374 ↗ |
| Known as | Amoxicillin-Potassium Clavulanate (generic drug) | “Amoxicillin-Potassium Clavulanate (generic drug)” NCT02783404 ↗ |
| Route | Oral | “500mg of Amoxicillin-Potassium Clavulanate Combination orally twice a day” NCT01919411 ↗ |